Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FULGENT GENETICS, INC.

(FLGT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
91.75(c) 86.6(c) 89.4(c) 97.58(c) 97.01(c) Last
417 895 518 064 317 860 961 635 560 888 Volume
-2.37% -5.61% +3.23% +9.15% -0.58% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 930 M - -
Net income 2021 483 M - -
Net Debt 2021 - - -
P/E ratio 2021 6,23x
Yield 2021 -
Sales 2022 561 M - -
Net income 2022 188 M - -
Net Debt 2022 - - -
P/E ratio 2022 16,1x
Yield 2022 -
Capitalization 2 894 M 2 894 M -
Capi. / Sales 2021 3,11x
Capi. / Sales 2022 5,15x
Nbr of Employees 480
Free-Float 66,9%
More Financials
Company
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. The Company's... 
More about the company
Ratings of Fulgent Genetics, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about FULGENT GENETICS, INC.
11/09FULGENT GENETICS, INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/09Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/09Fulgent Genetics Reports Third Quarter Financial Results - Form 8-K
PU
11/09Fulgent Genetics Seeks M&A
CI
11/09Fulgent Genetics Reports Higher Q3 Non-GAAP EPS as Revenue More Than Doubles, Lifts 202..
MT
11/09FULGENT GENETICS, INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
11/09Fulgent Genetics Reports Third Quarter Financial Results
BU
11/09Earnings Flash (FLGT) FULGENT GENETICS Reports Q3 Revenue $227.9M, vs. Street Est of $2..
MT
11/09Earnings Flash (FLGT) FULGENT GENETICS Reports Q3 EPS $4.05, vs. Street Est of $3.25
MT
11/09Fulgent Genetics, Inc. Revises Earnings Guidance for the Full Year 2021
CI
11/09Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021
CI
11/09EARNINGS REACTION HISTORY : Fulgent Genetics Inc, 55.6% Follow-Through Indicator, 16.7% Se..
MT
11/09Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences
BU
11/08Helio Health Inc. and Fulgent Genetics, Inc. Announce New Positive Performance Data of ..
CI
11/04Fulgent Genetics Offers Multi-Omic Solutions to Pharma through Addition of Olink Proteo..
CI
More news
News in other languages on FULGENT GENETICS, INC.
11/09Fulgent Genetics annonce une hausse du bénéfice par action non GAAP au troisième trimes..
11/09Earnings Flash (FLGT) FULGENT GENETICS annonce un chiffre d'affaires de 227,9 millions ..
11/09Fulgent Genetics, Inc. donne ses prévisions de revenus pour le quatrième trimestre 2021
11/09Fulgent Genetics, Inc. révise ses prévisions de bénéfices pour l'ensemble de l'année 20..
11/09HISTORIQUE DES RÉACTIONS AUX BÉNÉFIC : Fulgent Genetics Inc, 55,6% d'indicateur de suivi, ..
More news
Analyst Recommendations on FULGENT GENETICS, INC.
More recommendations
Chart FULGENT GENETICS, INC.
Duration : Period :
Fulgent Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FULGENT GENETICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 97,01 $
Average target price 141,00 $
Spread / Average Target 45,3%
EPS Revisions
Managers and Directors
Ming Hsieh Chairman, President & Chief Executive Officer
Paul H. Kim Chief Financial Officer
Han Lin Gao Chief Scientific Officer & Laboratory Director
Lawrence M. Weiss Chief Medical Officer
James Xie Chief Operating Officer
Sector and Competitors